bullish
Innovent Biologics (1801.HK) - The Strength and the Concerns
180 Views31 Aug 2021 09:11
This article analyzed Innovent about 2021H1 performance, commercialized products, pipeline, concerns of the Company, and also include thoughts on when to reduce stock holdings or even sell-off.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO Imeik Technology Development (300896 CH) - Is High Profitability Sustainable?06 Sep 2021
- China Healthcare Weekly (Sep.3) - Price Reform of Medical Services, Medical Beauty, Functional Food05 Sep 2021
- Jiangsu Hengrui Medicine (600276.CH) - The Concerns and the Outlook02 Sep 2021
- Innovent Biologics (1801.HK) - The Strength and the Concerns31 Aug 2021
- Pre-IPO BeiGene Ltd - Concerns on Commercialization26 Jul 2021
- Industry Report - Insights on China Biological Drug Market18 Mar 2021
- Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma18 Feb 2021
x